Navigation Links
InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS)
Date:5/16/2011

on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes Esbriet® (pirfenidone), which is now approved in the European Union in adults for the treatment of mild to moderate IPF, a progressive and fatal lung disease.  The hepatology portfolio includes next-generation HCV protease inhibitor and NS5A research programs.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to commercial launch preparations, anticipated timing of commercial launch and statements regarding the various anticipated durations of patent protection and marketing exclusivity.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information.  InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.  

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 9, 2011 (the "Form 10-K"), and other periodic reports filed with the SEC, including but not limited to the foll
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InterMune to Present at Bank of America Merrill Lynch Health Care Conference
2. InterMune Reports First Quarter 2011 Financial Results and Business Highlights
3. InterMune to Release First Quarter Financial Results on April 28
4. InterMune to Release Fourth Quarter and Full Year Financial Results on February 16
5. InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbrietâ„¢ (Pirfenidone) in Europe
6. InterMune to Release Third Quarter Financial Results on October 28
7. InterMune Sells Danoprevir Rights to Roche for $175 Million
8. InterMune to Present at 2010 Citi Health Care Conference
9. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
10. InterMune to Release First Quarter Financial Results on April 29
11. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  Today, Americord Registry, one ... announced Andrew Horne , a partner at Kirkland & ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... Americord,s Advisory Board," says Martin Smithmyer , CEO of ... his legal career that will assist Americord,s growth and vision." ...
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome and ... insights on mechanics of fecal microbiota transplantation in C. difficile patients. , SAN ... of patients undergoing fecal microbiota transplantation (FMT) as a treatment for Clostridium difficile ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... does not sacrifice selectivity to achieve faster flow rates in comparison to nylon ... with significant open space to allow easy liquid flow while trapping particulates as ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... services to the federal government, announced in a paper published this week in ... a potential problem with the diagnostic techniques currently used to detect the Ebola ...
Breaking Biology Technology:Americord Registry Announces Andrew Horne as Advisory Board Member 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3New Nanofiber Membrane Provides Fast, Efficient Filtration 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4
... University of Wisconsin-Madison spinoff developing a drug for people with ... $1.6 million, of which it has received the first portion, ... developing drug candidates. , ,Trevor Twose, Mithridion's CEO, said the ... that he may hire six people by the end of ...
... was sent an announcement of pending Illinois broadband legislation ... Here's its synopsis: , Creates the Universal Access to ... Services (CMS) to create and maintain a map of ... publicly held broadband infrastructure shall be available for lease ...
... to a biotech company (it is priority #1, #2, and ... sense) companies are continually faced with the challenge of raising ... article will focus on venture capital financing results for 2005. ... from Burrill and Company's data. Burrill's perspective is more towards ...
Cached Biology Technology:Mithridion raises $1.6M through angel networks 2Proposed Illinois broadband act falls short 2Proposed Illinois broadband act falls short 3Proposed Illinois broadband act falls short 4Proposed Illinois broadband act falls short 5U.S. VC funding flat in 2005 while life science funding grows 2U.S. VC funding flat in 2005 while life science funding grows 3U.S. VC funding flat in 2005 while life science funding grows 4
(Date:6/30/2015)... June 30, 2015 To bolster its efforts and ... Corp. announced today the addition of two new team members. ... board advisor and David Raviv will act as ... HYPR Corp.,s commitment to providing the most secure solutions for ... co-founded Layer 7 Technologies, a provider of security and ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... This news release is available in German ... fever, diarrhoea -- these symptoms could point to an infection ... is based on a syringe-like injection apparatus called injectisome. For ... at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, ...
... oligodendrocyte precursor cells (OPC) migrate to the lesion and ... the Institute of Molecular Cell Biology at Johannes Gutenberg ... protein regulates the direction and movement of OPC toward ... at the surface of OPCs and down-regulated as they ...
... Western Reserve University has granted a two-year technology ... a hand-held device that diagnoses malaria more quickly, ... Diagnostic Group LLC, the startup formed last summer ... of Engineering, also raised $250,000 to "field-test" the ...
Cached Biology News:3-D molecular syringes 23-D molecular syringes 3Scientists at Mainz University decode mechanisms of cell orientation in the brain 2CWRU grants Disease Diagnostic Group option on malaria diagnostic device 2